Dr. Sudhir Manda
Claim this profileArizona Oncology Associates
Studies Lymphoma
Studies Colorectal Cancer
17 reported clinical trials
40 drugs studied
About Sudhir Manda
Education:
- Obtained MD from the University of Arizona College of Medicine, Tucson, AZ.
- Completed Residency in Internal Medicine at the University of Arizona College of Medicine, Tucson, AZ.
- Undertook Fellowship in Hematology/Oncology at the University of Arizona Cancer Center, Tucson, AZ.
Experience:
- Board-certified in Internal Medicine, Hematology, and Medical Oncology.
- Associated with Arizona Oncology Associates.
Area of expertise
1Lymphoma
metastatic
Stage IV
RECIST 1.1
2Colorectal Cancer
Stage IV
RECIST 1.1
Stage III
Affiliated Hospitals
Clinical Trials Sudhir Manda is currently running
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting1 award Phase 34 criteria
Selinexor + DRd
for Multiple Myeloma
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Recruiting1 award Phase 29 criteria
More about Sudhir Manda
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Sudhir Manda has experience with
- Lenalidomide
- Pembrolizumab
- Rituximab
- Dexamethasone
- LOXO-305
- Gemcitabine
Breakdown of trials Sudhir Manda has run
Lymphoma
Colorectal Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sudhir Manda specialize in?
Sudhir Manda focuses on Lymphoma and Colorectal Cancer. In particular, much of their work with Lymphoma has involved metastatic patients, or patients who are Stage IV.
Is Sudhir Manda currently recruiting for clinical trials?
Yes, Sudhir Manda is currently recruiting for 5 clinical trials in Tucson Arizona. If you're interested in participating, you should apply.
Are there any treatments that Sudhir Manda has studied deeply?
Yes, Sudhir Manda has studied treatments such as Lenalidomide, Pembrolizumab, Rituximab.
What is the best way to schedule an appointment with Sudhir Manda?
Apply for one of the trials that Sudhir Manda is conducting.
What is the office address of Sudhir Manda?
The office of Sudhir Manda is located at: Arizona Oncology Associates, Tucson, Arizona 85745 United States. This is the address for their practice at the Arizona Oncology Associates.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.